Rituximab in Newly Diagnosed Generalized Myasthenia Gravis: A New Treatment Paradigm?
JAMA Neurol
.
2022 Nov 1;79(11):1100-1102.
doi: 10.1001/jamaneurol.2022.2311.
Authors
Miguel Chuquilin
1
,
Richard Barohn
2
Affiliations
1
Department of Neurology, University of Florida, Gainesville.
2
Department of Neurology, University of Missouri School of Medicine, Columbia.
PMID:
36121665
DOI:
10.1001/jamaneurol.2022.2311
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Immunologic Factors / therapeutic use
Myasthenia Gravis* / drug therapy
Receptors, Cholinergic
Rituximab / therapeutic use
Substances
Rituximab
Receptors, Cholinergic
Immunologic Factors